

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

MDA-MB-436

RRID:CVCL_0623

Type: Cell Line

Proper Citation

RRID:CVCL_0623

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0623

Proper Citation: RRID:CVCL_0623

Description: Cell line MDA-MB-436 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Invasive breast carcinoma of no special type

Defining Citation: [PMID:730202](#), [PMID:1961733](#), [PMID:3518877](#), [PMID:7272986](#), [PMID:9288768](#), [PMID:9823299](#), [PMID:10862037](#), [PMID:10969801](#), [PMID:11343771](#), [PMID:15677628](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:17157791](#), [PMID:18516279](#), [PMID:19582160](#), [PMID:19593635](#), [PMID:21778573](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23151021](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25892236](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28287265](#), [PMID:28889351](#), [PMID:29273624](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MDA-MB-436

Synonyms: MDA_MB_436, MDA MB 436, MDA-Mb-436, MDA-MB436, MDAMB436, MDA-436, MDA436, MB436, MD Anderson-Metastatic Breast-436

Cross References: BTO:BTO_0001568, CLO:CLO_0007639, EFO:EFO_0001214, CLDB:cl7218, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:HTB-130, BioGRID_ORCS_Cell_line:553, BioSample:SAMN03471588, BioSample:SAMN03472712, BioSample:SAMN10987901, cancercellines:CVCL_0623, CCRID:1101HUM-PUMC000352, CCRID:3101HUMTCHu184, Cell_Model_Passport:SIDM00629, ChEMBL-Cells:ChEMBL4295382, ChEMBL-Targets:ChEMBL4296465, CLS:300278, Cosmic:809240, Cosmic:871156, Cosmic:897425, Cosmic:904382, Cosmic:934528, Cosmic:949191, Cosmic:979718, Cosmic:1010926, Cosmic:1017165, Cosmic:1027055, Cosmic:1044206, Cosmic:1044222, Cosmic:1046957, Cosmic:1071902, Cosmic:1176604, Cosmic:1287923, Cosmic:1289400, Cosmic:1309008, Cosmic:1434955, Cosmic:1609474, Cosmic:2009513, Cosmic:2164998, Cosmic:2361353, Cosmic-CLP:1240172, DepMap:ACH-000573, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240172, GEO:GSM115100, GEO:GSM149985, GEO:GSM149993, GEO:GSM150001, GEO:GSM217589, GEO:GSM344354, GEO:GSM344404, GEO:GSM350541, GEO:GSM421878, GEO:GSM783954, GEO:GSM844600, GEO:GSM844601, GEO:GSM845397, GEO:GSM847416, GEO:GSM847496, GEO:GSM887299, GEO:GSM888374, GEO:GSM1008909, GEO:GSM1053725, GEO:GSM1172982, GEO:GSM1214583, GEO:GSM1238135, GEO:GSM1374658, GEO:GSM1374659, GEO:GSM1401656, GEO:GSM1670085, GEO:GSM2258866, GEO:GSM2258867, GEO:GSM2258868, GEO:GSM2258869, GEO:GSM2258870, GEO:GSM2258871, GEO:GSM2258872, GEO:GSM2258873, GEO:GSM2258874, GEO:GSM2258875, GEO:GSM2258876, GEO:GSM2258877, GEO:GSM2258878, GEO:GSM2258879, GEO:GSM2258880, GEO:GSM2258881, GEO:GSM2258882, GEO:GSM2258883, GEO:GSM2258938, GEO:GSM2258939, GEO:GSM2258940, GEO:GSM3161722, GEO:GSM3161723, IARC_TP53:18371, IARC_TP53:26994, ICLC:HTL11005, IZSLER:BS TCL 246, LiGeA:CCLE_254, LINCS_HMS:50333, LINCS_LDP:LCL-1470, PharmacDB:MDAMB436_905_2019, PRIDE:PXD005292, PRIDE:PXD008222, PRIDE:PXD030304, Progenetix:CVCL_0623, PubChem_Cell_line:CVCL_0623, SLKBase:3609, TOKU-E:2399, Wikidata:Q54904639

ID: CVCL_0623

Record Creation Time: 20220427T220756+0000

Record Last Update: 20260829T234602+0000

Ratings and Alerts

No rating or validation information has been found for MDA-MB-436.

No alerts have been found for MDA-MB-436.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 839 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. *Cell reports. Medicine*, 7(4), 102694.

Ancona P, et al. (2026) Diving into AA9-mediated transglutaminase 2 inhibition reveals ferroptosis as driver of anticancer effects. *Biochemical pharmacology*, 250(Pt 2), 118037.

Pantazaka E, et al. (2026) Repurposing Artesunate to Combat Progression and Metastasis via Targeting Circulating Tumor Cells. *Oncology research*, 34(6), 13.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Suresh S, et al. (2025) PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cells. *Scientific reports*, 15(1), 36766.

Li H, et al. (2025) Mechanistic study of N-acetyltransferase 10 deficiency enhancing olaparib sensitivity in triple negative breast cancer by inhibiting RAD51 N4-acetylcytidine modification. *iScience*, 28(7), 112860.

Cheng TC, et al. (2025) Fibroblast growth factor receptor four inhibitor FGF401 improves the efficacy of trastuzumab in FGFR4-overexpressing breast cancer cells. *International journal of cancer*, 156(8), 1606.

Gallo M, et al. (2025) Metabolic Profiling of Breast Cancer Cell Lines: Unique and Shared Metabolites. *International journal of molecular sciences*, 26(3).

Pinho MP, et al. (2025) Tumor-specific CD8 T cell characterization in HR+ breast cancer reveals an impaired antitumoral response in patients with lymph node metastasis. *Cell reports. Medicine*, 6(8), 102252.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. *Cell reports. Medicine*, 6(12), 102478.

Wei J, et al. (2025) Protocol to identify small-molecule inhibitors against cancer drug resistance. *STAR protocols*, 6(1), 103605.

Xu W, et al. (2025) LINC01235 Is an Upstream Regulator of the NFIB Gene and the Notch Pathway in Triple-Negative Breast Cancer. *Molecular cancer research : MCR*, 23(10), 859.

Schreiber AR, et al. (2025) Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. *Frontiers in oncology*, 15, 1549282.

Avellino A, et al. (2025) An Olive Oil-Based High-Fat Diet Promotes Obesity-Driven Metastasis of Triple-Negative Breast Cancer. *Cancer research*, 85(24), 5015.

Li B, et al. (2025) Manipulating the cGAS-STING Axis: advancing innovative strategies for osteosarcoma therapeutics. *Frontiers in immunology*, 16, 1539396.

Patel SS, et al. (2025) Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine. *Cancer research communications*, 5(3), 458.

Pequerul R, et al. (2025) Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors. *Cell chemical biology*.

Komar ZM, et al. (2025) Curcumin Induces Homologous Recombination Deficiency by BRCA2 Degradation in Breast Cancer and Normal Cells. *Cancers*, 17(13).

Schwarz E, et al. (2025) Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer. *Cancer immunology research*, 13(4), 560.

Abrams RPM, et al. (2025) An engineered cysteine sensor optimized for high-throughput screening identifies regulators of intracellular thiol levels. *Cell chemical biology*, 32(11), 1381.